Loading
ImmuCell Corporation functions as an animal health enterprise, specializing in the creation, manufacturing, and commercialization of offerings aimed at improving the vitality and output of dairy and beef cattle, serving both the U.S. domestic market and international regions. Among its key products is First Defense, an orally administered preventative designed to combat scours in newborn dairy and beef calves. The company also provides Tri-Shield First Defense, a passive antibody treatment effective against E. coli, coronavirus, and rotavirus. Additionally, ImmuCell offers the California Mastitis Test, a diagnostic instrument used to quantify somatic cell counts in milk and identify which specific udder quarter may be affected by mastitis. Its Dual-Force First Defense product, incorporating a whey protein concentrate, caters to the nutritional and animal feed supplement industries. Currently under development is Re-Tain, a Nisin-based intramammary therapy targeting subclinical mastitis in lactating dairy cows. The company primarily distributes its products through a network of animal health distributors. ImmuCell Corporation was established in 1982 and is based in Portland, Maine.
Previous close
$9.84
−$0.06 · -0.61%
After-hours
$9.84
$0.00 · 0.00%
Sep 8, 4:10 PM ET
Regular session · ET · Market data may be delayed.
ImmuCell Corporation functions as an animal health enterprise, specializing in the creation, manufacturing, and commercialization of offerings aimed at improving the vitality and output of dairy and beef cattle, serving both the U.S. domestic market and international regions. Among its key products is First Defense, an orally administered preventative designed to combat scours in newborn dairy and beef calves. The company also provides Tri-Shield First Defense, a passive antibody treatment effective against E. coli, coronavirus, and rotavirus. Additionally, ImmuCell offers the California Mastitis Test, a diagnostic instrument used to quantify somatic cell counts in milk and identify which specific udder quarter may be affected by mastitis. Its Dual-Force First Defense product, incorporating a whey protein concentrate, caters to the nutritional and animal feed supplement industries. Currently under development is Re-Tain, a Nisin-based intramammary therapy targeting subclinical mastitis in lactating dairy cows. The company primarily distributes its products through a network of animal health distributors. ImmuCell Corporation was established in 1982 and is based in Portland, Maine.
Day range
Current $9.84
52-week range
Current $9.84
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
64
Undervalued
Sentiment
64
Bullish
Risk
46
Elevated Risk
Momentum
77
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
ImmuCell Corporation functions as an animal health enterprise, specializing in the creation, manufacturing, and commercialization of offerings aimed at improving the vitality and output of dairy and beef cattle, serving both the U.S. domestic market and international regions. Among its key products is First Defense, an orally administered preventative designed to combat scours in newborn dairy and beef calves. The company also provides Tri-Shield First Defense, a passive antibody treatment effective against E. coli, coronavirus, and rotavirus. Additionally, ImmuCell offers the California Mastitis Test, a diagnostic instrument used to quantify somatic cell counts in milk and identify which specific udder quarter may be affected by mastitis. Its Dual-Force First Defense product, incorporating a whey protein concentrate, caters to the nutritional and animal feed supplement industries. Currently under development is Re-Tain, a Nisin-based intramammary therapy targeting subclinical mastitis in lactating dairy cows. The company primarily distributes its products through a network of animal health distributors. ImmuCell Corporation was established in 1982 and is based in Portland, Maine.
Day range
Current $9.84
52-week range
Current $9.84
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 27.64M USD | 26.49M USD | 17.47M USD | 18.57M USD | 19.24M USD |
| Cost of goods sold | 16.2M USD | 18.55M USD | 13.08M USD | 10.92M USD | 10.59M USD |
| Gross profit | 11.45M USD | 7.94M USD | 4.4M USD | 7.65M USD | 8.66M USD |
| Research and development | 3.04M USD | 3.9M USD | 4.39M USD | 4.49M USD | 4.17M USD |
| Selling, general, and administrative | 6.75M USD | 5.68M USD | 5.22M USD | 5.45M USD | 4.23M USD |
| Operating expenses | 9.8M USD | 9.58M USD | 10.14M USD | 9.95M USD | 8.4M USD |
| Interest income | 158.71K USD | 77.7K USD | 96.57K USD | 153.1K USD | 18.81K USD |
| Interest expense | 439.04K USD | 568.73K USD | 452.98K USD | 348.54K USD | 314.36K USD |
| Depreciation and amortization | 2.73M USD | 2.69M USD | 2.72M USD | 2.49M USD | 2.46M USD |
| Operating income | 1.65M USD | −1.64M USD | −5.75M USD | −2.3M USD | 257.39K USD |
| Net income | −1.04M USD | −2.16M USD | −5.77M USD | −2.49M USD | −78.29K USD |
Company facts updated Sep 9, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI2.03M0.00%2.3T USD0.03%$377.6-0.56%
Vanguard Extended Market ETFVXF885.44K0.00%93.7B USD0.05%$241.35-0.54%
iShares Micro-Cap ETFIWC210.98K0.01%1.49B USD0.60%$195.17-0.74%
Dimensional - US Targeted Value ETFDFAT27.37K0.00%14.53B USD0.28%$70.95-1.21%
Dimensional - US Core Equity 1 ETFDCOR18.89K0.00%3.53B USD0.14%$84.17-0.78%
U.S. Micro Cap Portfolio ETFDFMC17.45K0.00%7.82B USD0.43%$59.8689-0.81%
Dimensional - US Sustainability Core 1 ETFDFSU5.59K0.00%2.35B USD0.15%$47.955-0.96%
Dimensional - US Core Equity 2 ETFDFAC1.06K0.00%49.18B USD0.17%$45.38-0.74%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCDimensional - US Targeted Value ETFDFATDimensional - US Core Equity 1 ETFDCORU.S. Micro Cap Portfolio ETFDFMCDimensional - US Sustainability Core 1 ETFDFSUDimensional - US Core Equity 2 ETFDFACAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
